Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10056843 | 0.97 | ACE (0.48) | DPP4ACEDPP7DPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL572193 | 0.87 | DPP4 (0.53) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL10057885 | 0.85 | ACE (0.55) | ACEXIAP | |
| SCHEMBL572136 | 0.85 | ACE (0.55) | ACEXIAP | |
| SCHEMBL10057505 | 0.84 | DPP4 (0.56) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL10057507 | 0.80 | DPP4 (0.51) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL14973572 | 0.79 | DPP4 (0.51) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL572754 | 0.77 | KLK5 (0.44) | DPP4ACEDPP7DPP8DPP9 | |
| SCHEMBL6878507 | 0.77 | ACE (0.62) | DPP4ACEDPP7DPP8DPP9 | |
| SCHEMBL6878794 | 0.77 | ACE (0.62) | DPP4ACEDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600888-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Pharmaceuticals Ltd. (IN) | 2013-06-12 | — | — | EP | claimed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | claimed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | claimed |
| EP-2600888-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Pharmaceuticals Ltd. (IN) | 2013-06-12 | — | — | EP | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885KCNH2 2773/4885ACE 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.